August 26, 2013

The Food and Drug Administration approved a new drug made by Ceptaris Therapeutics for treating a type of lymphoma, the company said.

August 8, 2013

Eisai announced that the Food and Drug Administration has granted orphan drug designation to its investigational compound (E7777) for cutaneous T-cell lymphoma.

February 21, 2013

Valeant Pharmaceuticals has bought rights to a drug used to treat skin cancer from Eisai, the companies said Thursday.

May 9, 2012

Seattle Genetics and Takeda's cancer drug subsidiary have started a late-stage clinical trial for a lymphoma drug, the companies said Wednesday.

October 11, 2011

The Food and Drug Administration has accepted the first regulatory approval application for a generic version of a cancer drug made by Eisai.